What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3).

Efficacy and Safety of Stapokibart in Adults With Moderate‐to‐Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 Trial

View Full Paper

Ask AI

Bookmark

To compare the efficacy and safety of stapokibart in adults with moderate‐to‐severe atopic dermatitis with and without type 2 comorbidities.
Double‐blind phase 3 trial design
Participants received stapokibart or placebo every other week
Comorbidities included allergic rhinitis, asthma, food allergies, chronic urticaria
Responses measured using EASI, IGA, and PP‐NRS scores during treatment
Stapokibart group had higher response rates in EASI-75 (77.2% vs 26.5%) compared to placebo in patients with comorbidities
Higher response rates in IGA 0/1 (55.4% vs 17.6%) and PP‐NRS4 (43.5% vs 12.7%) in the same group
In non-comorbid patients, EASI-75 response rates were 61.0% for stapokibart, compared to 25.3% for placebo
Overall, treatment-emergent adverse events occurred in 88.8% of patients with comorbidities and 87.7% without

No takes yet. Share an insight, caveat, or question.

Post hoc analysis reveals stapokibart improves efficacy in patients with atopic dermatitis, highlighting type 2 comorbidities.

Zhao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark